

## Mechanisms and Efficacy of Traditional Chinese Medicine in the Management of Sepsis with Multiple Organ Dysfunction

Thabo Mokoena<sup>1</sup>, Siphso Dlamini<sup>1</sup>, Marius van der Merwe<sup>1\*</sup>

<sup>1</sup>Department of Clinical Sciences, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa.

\*E-mail ✉ [marius.vdm@outlook.com](mailto:marius.vdm@outlook.com)

Received: 14 January 2024; Revised: 19 March 2024; Accepted: 21 March 2024

### ABSTRACT

Sepsis is increasingly recognized not just as an infection-triggered systemic inflammatory response but as a life-threatening condition marked by organ dysfunction resulting from a dysregulated host response. Among its most severe consequences is multiple organ dysfunction syndrome (MODS), which significantly worsens patient prognosis. Currently, effective pharmacological interventions for sepsis and sepsis-induced MODS are limited, and mortality remains high. Traditional Chinese medicine (TCM) offers extensive experience in both preventing and managing sepsis, with its diverse bioactive compounds, molecular targets, and pathways contributing to therapeutic effects. This review systematically searched CNKI, Wanfang, PubMed, and Web of Science using the keywords ‘Sepsis,’ ‘Organ dysfunction,’ and ‘Traditional Chinese medicine’ to examine the role of TCM formulations in addressing sepsis with MODS. The study summarizes the current understanding of TCM strategies, providing insights to support clinical practice and guide the development of novel therapeutic agents.

**Keywords:** Multiple organ dysfunction syndrome, Sepsis, Traditional Chinese medicine, Therapeutic strategies

**How to Cite This Article:** Mokoena T, Dlamini S, van der Merwe M. Mechanisms and Efficacy of Traditional Chinese Medicine in the Management of Sepsis with Multiple Organ Dysfunction. *Interdiscip Res Med Sci Spec.* 2024;4(1):128-35. <https://doi.org/10.51847/js4VTQDy0I>

### Introduction

Sepsis is a life-threatening condition characterized by organ dysfunction resulting from a dysregulated host response to infection, which can originate in any part of the body [1]. In the United States, epidemiological data indicate that sepsis affects roughly 1.7 million adults annually, contributing to around 250,000 deaths each year [2]. In contrast, comprehensive epidemiological data on sepsis in mainland China remain limited. A 2023 study in Beijing reported that 13.1% of hospitalized patients developed sepsis, with an in-hospital mortality rate of 28.4%. After adjustment for age and sex, the standardized incidence was 421.85 per 100,000, with a mortality rate of 19.16 per 100,000 [3].

Effective management of sepsis requires early recognition of clinical signs and identification of the infectious source, followed by timely intervention to control the immune response. Untreated or delayed treatment can lead to septic shock and multiple organ dysfunction syndrome (MODS), which represents the severe end of systemic inflammatory dysregulation and accounts for more than 5.3 million deaths worldwide annually [4]. Research by Xue *et al.* [5] found that the incidence of secondary MODS within 28 days among hospitalized sepsis patients was 13.33%. Moreover, mortality in sepsis patients who develop MODS can reach 60%–80% [6], highlighting the critical need for effective prevention and treatment strategies.

The high morbidity and mortality associated with sepsis-induced MODS, coupled with the lack of optimal clinical therapies, make it a major focus of research. Conventional Western medicine primarily relies on antibiotics and supportive care [7]. However, antibiotic therapy may disrupt the systemic microbiota and contribute to the emergence of antibiotic resistance [8].

Advances in modern medicine and molecular biology have expanded the application of traditional Chinese medicine (TCM) in the management of sepsis. In TCM, sepsis falls under the category of febrile diseases [9] and is classified based on severity into sepsis, severe sepsis, and septic shock. TCM is increasingly integrated with standard antibiotic therapy as a complementary approach [10]. Evidence from meta-analyses indicates that herbal medicines play a significant role in mitigating sepsis by modulating inflammatory responses and reducing cytokine production [11]. TCM interventions have been shown to improve organ function and help maintain systemic homeostasis [12].

This review aims to summarize the current understanding of TCM strategies and their bioactive components in the treatment of sepsis and MODS, providing a theoretical foundation for their clinical application.


#### *Pathological mechanisms of sepsis with multiple organ dysfunction syndrome*

The pathophysiology of sepsis and multiple organ dysfunction syndrome (MODS) is highly intricate, involving the interplay of inflammatory responses, oxidative stress, and autophagy [13]. Two central host defense mechanisms against infection are the inflammatory response and the activation of coagulation pathways [13]. These processes are not isolated; rather, they interact synergistically and dynamically to respond to pathogenic challenges [13].

When an infectious agent is introduced, it triggers an acute immune reaction, primarily through macrophage activation and the release of pro-inflammatory cytokines, which can escalate into a cytokine storm. This response is mediated by pattern recognition receptors (PRRs), with Toll-like receptors (TLRs) being the most extensively studied [14]. TLRs recognize pathogen-associated or damage-associated molecular patterns and initiate several signaling cascades, including the mitogen-activated protein kinase (MAPK) and nuclear factor-kappa B (NF- $\kappa$ B) pathways, resulting in the production of inflammatory mediators [14]. The NF- $\kappa$ B pathway serves as a central hub linking inflammation and thrombosis [15]. It is expressed in vascular and circulating cells involved in thromboinflammatory processes and regulates the expression of cytokines, chemokines, and coagulation factors [15]. Through mechanisms such as neutrophil extracellular trap (NET) formation or endothelial injury caused by mechanical stress, the interconnection between inflammation and thrombosis can prompt rapid platelet activation and aggregation, contributing to thromboinflammatory complications observed in sepsis [15].

Oxidative stress, primarily induced by reactive oxygen species such as superoxide and hydrogen peroxide, disrupts mitochondrial dynamics, impairs adenosine triphosphate (ATP) production, and promotes neuronal damage [16]. These oxidative effects elevate caspase-3 and caspase-9 activation, alter the Bax/Bcl2 ratio in hippocampal and cortical neurons, and contribute to cognitive deficits seen in sepsis-associated encephalopathy [16].

Autophagy constitutes another essential host defense mechanism, protecting against invading pathogens and harmful stimuli [17]. It regulates inflammatory responses in innate immune cells and plays a pivotal role in sepsis progression. Protective effects of autophagy include pathogen clearance, neutralization of microbial toxins, modulation of cytokine release, inhibition of apoptosis, and enhancement of antigen presentation [17]. Specifically, upregulation of Beclin-1 has been shown to attenuate cardiac inflammation and tissue damage, preserve mitochondrial content, and improve cardiac function following lipopolysaccharide-induced injury [18]. Enhanced Beclin-1 signaling can also suppress mitochondrial reactive oxygen species generation, thereby maintaining autophagic activity even under severe septic conditions (**Figure 1**) [18].



**Figure 1.** Pathological mechanisms of sepsis and MODS.

### *Coagulation abnormalities and traditional chinese medicine in sepsis with MODS*

Coagulation activation is a fundamental defense mechanism against infection; however, in patients with sepsis, coagulation processes are frequently dysregulated [19]. Such coagulation disorders can contribute to the development of multiple organ dysfunction via microvascular thrombosis [19]. Consequently, maintaining proper coagulation function and minimizing the impact of coagulation abnormalities on organ systems are critical strategies for preventing and managing MODS in sepsis.

The etiology and pathogenesis of sepsis are complex, and traditional Chinese medicine (TCM) emphasizes treatment based on syndrome differentiation. Wang summarized sepsis pathogenesis under the principle of “three syndromes and three methods,” which include: toxin-heat syndrome treated with heat-clearing and detoxifying methods, blood stasis syndrome treated with approaches to promote blood circulation and remove stasis, and acute deficiency syndrome addressed with Fu Zheng–Gu Ben prescriptions [20, 21]. In clinical practice, TCM typically utilizes compound formulations rather than single herbs, with treatment tailored to the patient’s syndrome presentation [22]. Furthermore, TCM and its active components have demonstrated potential in combating antibiotic-resistant bacteria, offering novel strategies to overcome resistance associated with conventional antibiotic therapy in sepsis with MODS [22].

### *Traditional Chinese medicine for diagnosis and management of sepsis with MODS*

#### *Toxic-fever symptoms and heat-clearing/detoxifying methods*

In sepsis with MODS, toxic-fever symptoms manifest as persistent high fever, dizziness, nausea, vomiting, red tongue with yellow or dry coating, and a weak and rapid pulse [23]. The TCM approach for these symptoms primarily involves heat clearance and detoxification [23].

#### *Rhubarb-derived anthraquinones*

A literature search using the terms “sepsis,” “organ dysfunction,” and “heat clearing and detoxification” across PubMed and China National Knowledge Infrastructure identified rhubarb as the most frequently used herb in heat-clearing and detoxifying TCM formulations. Rhubarb contains diverse bioactive constituents, including anthraquinones, organic acids, volatile oils, glycosides, and tannins [24]. It has demonstrated wide-ranging therapeutic effects, such as regulating the digestive and circulatory systems, enhancing metabolism, supporting kidney function, reducing pain, preventing lung injury, mitigating oxidative stress, and exerting anti-inflammatory, antibacterial, antiviral, and antitumor actions [24].

The primary active anthraquinones—emodin, rhein, and chrysophanol—are also found in other commonly used TCM plants, such as *Polygonum cuspidatum* and *Polygonum multiflorum*, and have been extensively studied for both clinical and experimental applications [25]. Xu *et al.* [26] reported that emodin mitigates myocardial damage in septic rats by reducing oxidative stress, apoptosis, and inflammatory factor levels in cardiac tissue. Similarly, Dong *et al.* [27] demonstrated that emodin pretreatment in mice with lipopolysaccharide-induced sepsis-associated brain injury significantly decreases inflammatory cytokines such as IL-6 and markers of neuronal injury, likely through cholinergic pathway activation and suppression of inflammatory responses. Chrysophanol has been shown to induce M2 macrophage polarization, reduce lung injury, inhibit NF- $\kappa$ B p65 and ERK1/2 signaling pathways, and downregulate cleaved caspase-3 and -9 in septic rats [28].

Furthermore, intraperitoneal administration of emodin in septic rats reduces oxidative stress and inflammatory infiltration in heart, liver, lung, and kidney tissues, providing organ-protective effects [29]. Lin *et al.* [30] observed that septic rats initially display hypocoagulability, with reduced fibrin and platelet activity, followed by compensatory hypercoagulability. Emodin enhances endogenous coagulation factor activity and fibrinogen function, thereby lowering 48-hour mortality rates in septic animals. These findings highlight emodin’s therapeutic potential in modulating coagulation disturbances, particularly in the context of sepsis-induced multiple organ dysfunction.

#### *Berberine*

*Coptis chinensis* is a widely used TCM herb for heat clearing and detoxification, ranking second only to rhubarb in frequency of use for sepsis-related prescriptions [31]. Berberine, a major bioactive alkaloid extracted from *C. chinensis*, exhibits significant anti-inflammatory effects in both acute and chronic contexts [31]. Both berberine and *C. chinensis* can enhance leukocyte phagocytic activity in vitro and in vivo, thereby partially modulating the inflammatory response [31]. Administration of berberine in mice with *Escherichia coli*-induced sepsis increased survival rates and enhanced the efficacy of antibiotics, primarily through regulation of T lymphocytes and reduction of inflammatory cytokines such as IL-6, suggesting its utility in both prevention and treatment of sepsis [32].

Berberine also demonstrates protective effects against sepsis-induced multiple organ dysfunction. In mice with sepsis and acute respiratory distress syndrome, berberine pretreatment resulted in lower lung injury scores, reduced serum inflammatory markers, and significantly decreased NF- $\kappa$ B p65 levels in lung tissue, indicating inhibition of aberrantly activated NF- $\kappa$ B signaling as a potential mechanism [33]. Chen *et al.* [34] reported that berberine mitigates septic cardiomyopathy in rats by suppressing TLR4/NF- $\kappa$ B pathway activation, improving left ventricular end-diastolic pressure, and reducing lipopolysaccharide-induced cardiomyocyte swelling.

Experimental and clinical evidence indicates that berberine protects the intestinal epithelium during sepsis by modulating both intrinsic and extrinsic apoptosis pathways, thereby preserving intestinal mucosal integrity [35, 36]. High-mobility group protein 1 (HMGB1), a damage-associated molecular pattern (DAMP) protein, acts as a chemotactic cytokine in conditions such as infection, sepsis, hypoxia, and ischemia-reperfusion, serving as a key alarm signal for systemic imbalance [37]. Berberine may exert part of its protective effect through HMGB1-related pathways; Shi *et al.* [38] showed that berberine inhibits AGE-mediated HMGB1 signaling, reduces microglia-induced A1 astrocyte stress, and mitigates sepsis-associated cognitive impairment, preventing sepsis-related encephalopathy.

#### *Tetramethylpyrazine*

*Ligusticum chuanxiong* is traditionally used in TCM to promote blood and Qi circulation, alleviate liver stagnation, expel wind, and relieve pain [39]. Ligustrazine, a non-volatile alkaloid derived from *Rhizoma chuanxiong*, represents a major active component with significant pharmacological activity [39]. Clinical investigations have primarily focused on Danshen ligustrazine injections, while animal studies have explored ligustrazine's effects on sepsis-related organ dysfunction [40–44].

Regarding sepsis-induced renal injury, Ying *et al.* [40] demonstrated that ligustrazine significantly reduced renal water content and urinary levels of kidney injury molecule-1 in mice, mitigating renal damage. This protective effect is believed to involve caspase-3 inhibition, downregulation of anti-NMDA receptor activity, and anti-apoptotic properties. For sepsis-related cerebral and pulmonary injury, Huang *et al.* [41] found that ligustrazine attenuated inflammatory cell infiltration and tissue damage in the brain and lungs of septic rats, enhancing the expression of tight-junction proteins claudin-5 and occludin and preserving blood–brain barrier integrity. Wang *et al.* [42] reported that ligustrazine inhibited the p38 MAPK/CREB pathway, reducing hippocampal inflammation in sepsis-associated encephalopathy. Additionally, Liu *et al.* [43] showed that ligustrazine prevented apoptosis of pulmonary microvascular endothelial cells via modulation of the ER stress-associated PERK pathway, improving oxygenation and survival in septic rats with acute lung injury. In liver protection, ligustrazine-pretreated rats exhibited better mitochondrial function and overall hepatic performance in sepsis-induced acute liver injury models [44]. Zhang *et al.* [45] revealed that ligustrazine reduced hepatic iron accumulation by inhibiting JAK/STAT phosphorylation, thereby alleviating systemic inflammatory and liver injury. Similarly, Xiao *et al.* [46] demonstrated hepatoprotective effects of combined *Salvia miltiorrhiza* and ligustrazine injection in septic mice. Clinical studies further confirmed that ligustrazine antagonizes TNF- $\alpha$ , improves microcirculation, and, when combined with standard therapy, mitigates myocardial damage in septic patients [47]. Prophylactic administration of *S. miltiorrhiza* and ligustrazine injections also reduced systemic inflammatory response in severe burn patients, though the incidence of MODS remained unaffected [48]. While numerous animal studies validate ligustrazine's efficacy in sepsis and MODS, clinical evidence remains limited, highlighting the need for further research.

#### *Acute deficiency syndrome and fu Zheng–Gu ben therapy*

Acute deficiency syndrome in sepsis manifests as either Yin or Yang deficiency [21]. Yin deficiency is characterized by restlessness, flushed face, oliguria or anuria, a red and dry tongue, and bradycardia. Yang deficiency presents with cold sweats, cold extremities, dizziness, pale or purple tongue, and weak or irregular pulse. Fu Zheng–Gu Ben prescriptions are the primary TCM approach for treating these syndromes [21].

#### *Ginsenosides*

Ginseng, a principal Qi-invigorating herb, is frequently used in Fu Zheng–Gu Ben formulations. Its bioactive constituents—including ginsenosides, polysaccharides, volatile oils, and amino acids—exhibit anti-fatigue, anti-aging, antioxidant, and immunomodulatory effects [49]. Multiple studies have investigated ginsenosides in sepsis-related MODS, including liver, lung, myocardial, and neurological injury [50–55].

Wu *et al.* [50] demonstrated that ginsenosides upregulate taurine-upregulated gene 1 and downregulate miR-200a-3p, activating the SIRT1/AMPK pathway to enhance autophagy, thereby improving liver injury and mitochondrial dysfunction in septic models. Ginsenosides also protect type II alveolar epithelial cells from LPS-induced apoptosis by promoting autophagy and inducing Nrf2 expression, contributing to lung injury mitigation [51]. Zhang *et al.* [52] reported reduced pulmonary inflammation, decreased alveolar cytokines, and lowered NF- $\kappa$ B activation in ginsenoside-treated septic mice, confirming their anti-inflammatory effects. Ji *et al.* [53] observed that LPS-induced autophagy initially increases to reduce apoptosis and that ginsenosides further modulate this response, providing lung protection.

Cardiomyocyte apoptosis and inflammation in sepsis involve TLR4, NF- $\kappa$ B, and NLRP3 pathways [54]. Ginsenosides inhibit these pathways, attenuating myocardial apoptosis and restoring cardiac function. In sepsis-associated encephalopathy, ginsenosides suppress abnormal activation of NF- $\kappa$ B and MAPK signaling, regulating cytokine and chemokine levels to reduce neural damage [55].

#### **Conclusion**



As an integral component of complementary and integrative medicine, traditional Chinese medicine (TCM) has demonstrated significant therapeutic potential in managing acute and critical conditions, including sepsis complicated by multiple organ dysfunction syndrome (MODS). This review highlights that TCM exerts multiple beneficial effects in sepsis management, such as anti-inflammatory activity, improvement of microcirculation, mitigation of gastrointestinal dysfunction, immune system modulation, and protection of vital organs, thereby contributing to the alleviation of MODS. Future studies should focus on elucidating the mechanisms and efficacy of TCM in treating sepsis-induced MODS, supporting the development of novel therapeutic agents and the design of prospective, randomized controlled clinical trials to validate the clinical application of its active components.

**Acknowledgments:** None

**Conflict of Interest:** None

**Financial Support:** None

**Ethics Statement:** None

## References

1. T.T. Fan, B.L. Cheng, X.M. Fang, et al., Application of Chinese medicine in the management of critical conditions: a review on sepsis, *Am. J. Chin. Med.* 48 (6) (2020) 1315–1330.
2. C. Rhee, T.M. Jones, Y. Hamad, et al., Prevalence, underlying causes, and preventability of sepsis-associated mortality in US acute care hospitals, *JAMA Netw Open* 2 (2) (2019), e187571.
3. W. Li, X. Yang, Y. Pin, et al., National incidence and mortality of hospitalized sepsis in China, *Crit. Care* 27 (1) (2023) 84.
4. R.J. Zou, J. Tao, J.X. Qiu, et al., DNA-PKcs promotes sepsis-induced multiple organ failure by triggering mitochondrial dysfunction, *J. Adv. Res.* 41 (2022) 39–48.
5. H. Xue, X.H. Yan, L. Liang, et al., Logistic regression analysis of risk factors for multiple organ dysfunction syndrome secondary to sepsis, *Pediatr. Crit. Care Med.* 18 (4) (2017) 319–329.
6. B. Wang, Z.Y. Wang, R. Xu, et al., Correlation between lactate/albumin ratio level and incidence of multiple organ dysfunction syndrome as well as mortality in patients with sepsis Chin, *J Infect Control* 16 (5) (2011) 417–422 (in Chinese).
7. A.K. Varkouhi, A. Monteiro, J.N. Tsoporis, S. Mei, D.J. Stewart, S.C. Dos, Genetically modified mesenchymal stromal/stem cells: application in critical illness, *Stem Cell Rev. Rep.* 16 (5) (2020) 812–827.
8. J. Faura, A. Bustamante, F. Miro'-Mur, J. Montaner, Stroke-induced immunosuppression: implications for the prevention and prediction of post-stroke infections, *J. Neuroinflammation.* 18 (1) (2021) 127.
9. X.H. Wang, D.Q. Xu, Y.Y. Chen, S.J. Yue, R.J. Fu, L. Huang, Y.P. Tang, Traditional Chinese Medicine: a promising strategy to regulate inflammation, intestinal disorders and impaired immune function due to sepsis, *Front. Pharmacol.* 13 (2022), 952938.
10. L. Liu, Y. Shi, Z. Li, L. Zuo, M. Tang, Z. Jing, et al., Metabolomic insights into the synergistic effect of biapenem in combination with xuebijing injection against sepsis, *Front. Pharmacol.* 11 (2020) 502.
11. Y. Wen, C. Feng, W. Chen, C. Chen, S. Kuang, F. Liu, et al., Effect of traditional Chinese medicine on serum inflammation and efficacy in patients with sepsis: a systematic review and meta-analysis, *Ann. Palliat. Med.* 10 (12) (2021) 12456–12466.
12. Xingcai Yang, Wei Hong, Tianhong Zheng, et al., Clinical study on the protective effect of traditional Chinese medicine anti-inflammatory mixture on multiple organ function in sepsis patients, *Chinese Journal of Emergency Medicine* 37 (10) (2017) 6, <https://doi.org/10.3969/j.issn.1002-1949.2017.10.004>.
13. T. Iba, J.H. Levy, Inflammation and thrombosis: roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis, *J. Thromb. Haemostasis* 16 (2) (2018) 231–241.
14. Z. Li, X. Qi, X. Zhang, et al., TRDMT1 exhibited protective effects against LPS-induced inflammation in rats through TLR4-NF- $\kappa$ B/MAPK-TNF- $\alpha$  pathway, *Animal Model Exp Med* 5 (2) (2022) 172–182.
15. M. Mussbacher, M. Salzmann, C. Brostjan, et al., Cell type-specific roles of NF- $\kappa$ B linking inflammation and thrombosis, *Front. Immunol.* 10 (2019) 85.

16. M. Gu, X.L. Mei, Y.N. Zhao, Sepsis and cerebral dysfunction: BBB damage, neuroinflammation, oxidative stress, apoptosis and autophagy as key mediators and the potential therapeutic approaches, *Neurotox Res* 39 (2) (2021) 489–503.
17. M. Huang, S. Cai, J. Su, The pathogenesis of sepsis and potential therapeutic targets, *Int. J. Mol. Sci.* 20 (21) (2019) 5376.
18. Y. Sun, Y. Cai, Q.S. Zang, Cardiac autophagy in sepsis, *Cells* 8 (2) (2019) 141.
19. X.W. Yuan, N. Jiang, B. Chen, et al., Research progress of single-flavor traditional Chinese medicine in the treatment of sepsis, *Journal of Basic Chinese Medicine* 23 (5) (2020) 736–739 (in Chinese).
20. J.D. Wang, Z.J. Li, Y.P. Li, Dialectical treatment of sepsis from "three evidences and three methods, *Chin. Crit. Care Med.* 18 (11) (2016) 643–644 (in Chinese).
21. S.H. Cao, J. Wang, Y. Li, From "simultaneous treatment of bacteriotoxins" to "four evidences and four methods"-Dialectical ideas on the combination of traditional Chinese medicine and western medicine in the treatment of multiple organ dysfunction syndrome deepening and perfection, *Chin. Crit. Care Med.* 17(11) (2014) 641–643 (in Chinese).
22. T. Su, Y. Qiu, X. Hua, B. Ye, H. Luo, D. Liu, et al., Novel opportunity to reverse antibiotic resistance: to explore traditional Chinese medicine with potential activity against antibiotics-resistance bacteria, *Front. Microbiol.* 11 (2020), 610070.
23. Y.F. Zhang, Q. Zhang, Y.M. Wang, Dialectical application of traditional Chinese medicine prescription in adjuvant treatment of sepsis, *Shaanxi Traditional Chinese Medicine* 40 (8) (2017) 1105–1108 (in Chinese).
24. L.X. Jin, L.J. Jin, Z.Q. Luan, et al., Research progress on chemical constituents and Pharmacology of rhubarb, *Information on Traditional Chinese Medicine* 37(1) (2009) 121–126 (in Chinese).
25. Dan Wang, Preparation of EMO/PSM Nanodrug Delivery System and Evaluation of its Therapeutic Effect on Experimental UC [J], 2023.
26. R.M. Xu, Z.Y. Shao, D.W. Wang, Protective effect of emodin on myocardial injury in sepsis rats, *Med J West China* 32 (1) (2019) 1443–1446 (in Chinese).
27. Y. Dong, G. Liu, L. Zhang, et al., Neuroprotective effect of emodin on acute brain injury in sepsis mice, *Med J Chin PLA* 44 (1) (2019) 13–19 (in Chinese).
28. P. Wei, J.X. Guo, D.Y. Yu, et al., Chrysophanol alleviates lung injury of sepsis rats by promoting macrophage M2 polarization, *Immunological Journal* 36 (9) (2020) 748–755 (in Chinese).
29. L.Y. Hu, J.Y. Tan, J. Shen, et al., Protective effect of emodin on oxidative stress and inflammation of various organs in rat model of cecum ligation perforation sepsis, *J Clin Pathol Res* 39 (7) (2021) 1388–1395 (in Chinese).
30. Q.W. Lin, J.H. Song, Q.B. Zeng, et al., Effect of emodin on coagulation disorders of septic rats, *Military Medical Journal of Southeast China* 20 (5) (2018) 464–470 (in Chinese).
31. L. Huang, Research progress on chemical constituents and pharmacological activities of active ingredients of *Coptis chinensis*, *Cardiovascular Disease Electronic Journal of integrated traditional Chinese and Western Medicine* 8 (17) (2020) 136–137 (in Chinese).
32. E. Pierpaoli, O. Cirioni, O. Simonetti, et al., Potential application of berberine in the treatment of *Escherichia coli* sepsis, *Nat. Prod. Res.* 35 (22) (2021 Nov) 4779–4784.
33. X.L. Wu, L. Yu, D. Long, et al., Study on the protective effects and mechanism of berberine hydrochloride on sepsis induced acute respiratory distress syndrome in mice, *The Journal of Practical Medicine* 35 (22) (2021) 3452–3456 (in Chinese).
34. H. Chen, Q. Liu, X. Liu, et al., Berberine attenuates septic cardiomyopathy by inhibiting TLR4/NF- $\kappa$ B signalling in rats, *Pharmaceut. Biol.* 59 (1) (2021 Dec) 121–128.
35. H.M. Li, Y. Xing, X.Y. Tang, et al., Berberine inhibits enterocyte apoptosis in septic mice, *Chin. J. Pathophysiol.* 32 (9) (2016) 1660–1665 (in Chinese).
36. L. Wang, W.J. Xie, J. Liu, et al., Protective effect of berberine on intestinal mucosal barrier function in patients with sepsis, *Modern Journal of Integrated Traditional Chinese and Western Medicine* 27 (16) (2017) 1733–1735 (in Chinese).
37. J. Xue, J.S. Suarez, M. Minaai, et al., HMGB1 as a therapeutic target in disease, *J. Cell. Physiol.* 236 (5) (2021 May) 3406–3419.
38. J. Shi, H. Xu, M.J. Cavagnaro, et al., Blocking HMGB1/RAGE signaling by berberine alleviates A1 astrocyte and attenuates sepsis-associated encephalopathy, *Front. Pharmacol.* 12 (2021), 760186.

39. Z.H. Pu, M. Dai, C. Peng, et al., Research progress on the material basis and pharmacological effects of alkaloids from Chuanxiong, *China Pharmacy* 31 (8) (2011) 1020–1024 (in Chinese).
40. J. Ying, J. Wu, Y. Zhang, et al., Ligustrazine suppresses renal NMDAR1 and caspase-3 expressions in a mouse model of sepsis-associated acute kidney injury, *Mol. Cell. Biochem.* 464 (1–2) (2020 Jan) 73–81.
41. Z.S. Huang, D.Q. Xie, L.J. Xu, et al., Tetramethylpyrazine ameliorates lipopolysaccharide-induced sepsis in rats via protecting blood-brain barrier, impairing inflammation and nitrous oxide systems, *Front. Pharmacol.* 11 (2020), 562084.
42. J. Wang, H. Zhu, C.S. Huang, et al., Role of p38 MAPK/CREB signaling pathway in tetramethylpyrazine-induced reduction of hippocampal inflammatory responses in mice with sepsis-associated encephalopathy, *Chinese Journal of Anesthesiology* 41 (7) (2019) 870–873 (in Chinese).
43. W. Liu, K. Liu, S. Zhang, et al., Tetramethylpyrazine showed therapeutic effects on sepsis-induced acute lung injury in rats by inhibiting endoplasmic reticulum stress protein kinase RNA-like endoplasmic reticulum kinase (PERK) signaling-induced apoptosis of pulmonary microvascular endothelial cells, *Med. Sci. Mon. Int. Med. J. Exp. Clin. Res.* 24 (2018) 1225–1231.
44. Y. Sheng, J. Wang, X. Tao, et al., Study on the protective effect of ligustrazine on the transporting function of hepatocellular mitochondria membrane in the septic rats, *Zhonghua Wei Zhong Bing Ji Jiu Yi Xue* 30 (10) (2020) 996–1000.
45. Y.W. Zhang, J. Wang, H. Zhu, et al., Ligustrazine regulates expression of hepcidin in septic mice and its mechanism, *Zhejiang Medical Journal* 43 (21) (2018) 2311–2315 (in Chinese).
46. L. Xiao, G.C. Mei, L.H. Wu, et al., Protective effect of danshen chuangxiongqin injection on acute liver injury in septic young rats based on Nrf2/HO-1 pathway, *J. Emerg. Tradit. Chin. Med.* 28 (9) (2019) 1585–1589 (in Chinese).
47. B.W. Liu, W. Hu, W.H. Hu, et al., Study on the cardioprotective effect of ligustrazine on patients with septic myocardial damage, *Zhejiang Journal of Integrated Traditional Chinese and Western Medicine* 28 (8) (2016) 639–641 (in Chinese).
48. Y. Lin, S.B. Ruan, X.D. Chen, et al., Effect of salviae miltiorrhizae and ligustrazine hydrochloride injection on the inflammatory factors of severe burn patients and the prevention of sepsis, *Hebei Medicine* 24 (3) (2013) 382–385 (in Chinese).
49. X.n. Yu, X.G. Feng, J.M. Zhang, et al., Research progress on chemical constituents and pharmacological effects of *Panax ginseng*, *Ginseng Research* 31 (1) (2016) 47–51 (in Chinese).
50. P. Wu, X. Yu, Y. Peng, et al., Ginsenoside Rg3 alleviates septic liver injury by regulating the lncRNA TUG1/miR-200c-3p/SIRT1 axis, *J. Inflamm.* 18 (1) (2021) 31.
51. Q. Ji, Z. Sun, Z. Yang, et al., Protective effect of ginsenoside Rg1 on LPS-induced apoptosis of lung epithelial cells, *Mol. Immunol.* 136 (2021 Aug) 168–174.
52. Z.B. Zhang, Q.P. Xu, Experimental study of ginsenoside Rg1 combined with antibiotics in the treatment of acute lung injury in mice with sepsis, *J. Sichuan Univ. (Eng. Sci. Ed.)* 51 (3) (2013) 371–375 (in Chinese).
53. Q.J. Ji, Z.R. Sun, Z.Z. Yang, et al., Effects of Rg<sub>1</sub> on LPS-induced apoptosis and autophagy of lung epithelial cells, *Zhongguo Zhongyao Zazhi* 44 (8) (2020) 1648–1653.
54. M. Luo, D. Yan, Q. Sun, et al., Ginsenoside Rg1 attenuates cardiomyocyte apoptosis and inflammation via the TLR4/NF-kB/NLRP3 pathway, *J. Cell. Biochem.* 121 (4) (2020 Apr) 2994–3004.
55. Y. Chen, M. Chi, X. Qiao, et al., Anti-inflammatory effect of ginsenoside Rg1 on LPS-induced septic encephalopathy and associated mechanism, *Curr. Neurovascular Res.* 19 (1) (2022) 38–46.